Virtual Library

Start Your Search

Fikri İcli



Author of

  • +

    P2.03 - Biology (Not CME Accredited Session) (ID 952)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.03-34 - The Relationship Between Treatment Response and Serum EGFR Level in Nonsmall Cell Lung Cancer  (ID 12081)

      16:45 - 18:00  |  Author(s): Fikri İcli

      • Abstract
      • Slides

      Background

      Early diagnosis and the improvement in the treatment options in cancer patients can prolong the survival in the majority of malignancies, although they add no benefit to the survival of patients with non-small cell lung cancer (NSCLC). Some patients with NSCLC respond to the treatment well while others do not. Therefore, new prognostic factors and biomarkers other than the stage of disease should be explored in NSCLC. The management of NSCLC may be different according to those biomarkers. The new biomarkers may help to the clinicians to identify who patients have poor prognosis and respond to the specific treatment.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      The aim of this study is to investigate whether there is a relationship between the response to treatment and serum level of active EGFR or not. Thirty-three patients with locally advanced, metastatic or recurrent non-small cell lung cancer were enrolled into this study. Cisplatin docetaxel treatment was planned for those patients. Baseline and at the end of second and forth cycle of the treatment, serum EGFR were measured. Patients were divided into 2 groups according to their response to the treatment.SPSS7.0 was used to analyse patient data. Student t test and Mann-Withney U tests were used for the comparison between the groups' averages. Spearmann rho and Ki square tests were used to evaluate the relationships between parameters. Kaplan-Meier method was used for the survival analysis.

      4c3880bb027f159e801041b1021e88e8 Result

      Of 33 patients, 4 were female and 29 were male. The average of age of patients was 52. 12 patients were stage III, 21 were relapsed or stage IV. Objective response rate and overall response rate were found 15.6%, 34.4% respectively. Progression occurred 34.4% among patients in the study. When serum EGFR level cut off is 0.080 fmol/ml, while in patients who didn't respond, the positivity of serum EGFR level was 55.6%, it was 80% in patients who responded. Baseline serum EGFR levels were higher in patients with stage III disease compared to those of patients with relapsed and stage IV disease. In patients who responded to the therapy, baseline serum EGFR levels were found higher than those of the patients who didn’t respond regardless of the stage. Following two cycles of treatment, if serum EGFR level is found high, then the probability to respond to the treatment increases significantly.

      8eea62084ca7e541d918e823422bd82e Conclusion

      In conclusion, the serum level of EGFR seems to be a useful biomarker for predicting and monitoring the response to the treatment in patients with NSCLC.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.